Physician profile
David Hahn
NPI 1457347817
$18,814.92
in general payments reported to CMS, 2019-2025
14 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $529 · 2021: $1,546 · 2022: $2,873 · 2023: $13K · 2024: $141 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $1,539 · Travel and Lodging: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,350.00 |
| Food and Beverage | $1,539.28 |
| Travel and Lodging | $962.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,368.97 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $1,537.50 | 2022 | |
| Alkermes, INC. | $1,468.70 | 2019-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $1,094.82 | 2019-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $782.61 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $461.27 | 2019-2022 | |
| Axsome Therapeutics, INC. | $331.32 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $268.49 | 2019 | |
| Neurocrine Biosciences, INC. | $144.48 | 2019-2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $106.68 | 2024 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $82.40 | 2021 | |
| Allergan, INC. | $76.73 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.94 | 2023 | Trintellix |
| Stryker Corporation | $34.01 | 2024 | T2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.